Trinity Biotech plc announced a collaboration with the University at Buffalo on March 18 2026 to develop and commercialize a suite of proprietary biomarkers for Sjögren’s syndrome.
The partnership combines the University’s research expertise in autoimmune diagnostics with Trinity’s IMMCO subsidiary, which will co‑develop and bring the tests to market. The collaboration targets an estimated 4 million U.S. patients, a group that is currently underdiagnosed and could benefit from objective, biomarker‑based testing.
In a statement, Trinity’s management said, "Sjögren's is a significantly underdiagnosed condition that imposes a major burden on patients. This collaboration further positions Trinity Biotech at the forefront of developing next generation autoimmune diagnostics. Our partnership with the University at Buffalo represents another pivotal step toward building a premium reference lab offering anchored in innovation, clinical value, and proprietary science."
The deal aligns with Trinity’s strategy to expand its high‑value specialty diagnostics portfolio and strengthen its U.S. reference laboratory footprint. While the company has faced declining revenues in recent quarters—attributable to disruptions in global HIV testing markets and manufacturing transitions—the partnership could open a new revenue stream and help offset those headwinds. Trinity’s transformation plan, which includes outsourcing manufacturing to improve profitability, positions the company to capitalize on the new biomarker platform once it reaches commercialization.
The collaboration also builds on a long‑standing relationship between the University and Trinity’s IMMCO Diagnostics, which has previously explored Sjögren’s biomarkers. By leveraging the University’s discoveries and Trinity’s commercial platform, the partnership aims to deliver earlier and more accurate detection of the disease, potentially improving patient outcomes and creating a differentiated product offering in a market that currently lacks objective testing.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.